Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Most patients respond to chemotherapy in the short term, but, particularly in the case of bladder cancer, patients who respond over the long term to a given drug are rare, and the cancer often recurs. Lee hopes that the model will help match patients with drugs that will work over the long term.

The gene chips used for the studies, made by Affymetrix, now cost only $260. Theodorescu says that this price is “trivial compared to imaging,” such as the magnetic resonance imaging and PET scans routinely used in clinical trials. And he says that the price could come down if researchers used Affymetrix chips customized for particular cancer types.

Most hospital laboratories don’t have the resources to perform and interpret gene-expression analysis. But Theodorescu hopes it will become a routine part of patient care in the next five or ten years, complementing the under-the-microscope tissue analysis currently used to characterize cancers.

2 comments. Share your thoughts »

Credit: Proceedings of the National Academy of Sciences.

Tagged: Biomedicine, cancer, drugs, tumor, chemotherapy

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me